Clinical Trials · NCT02231684
Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 42
- Start date
- Sep 2014
- Locations
- 1 site, Germany
- Primary endpoint
- Area under the semaglutide plasma concentration curve